Berkeley Lights' Announces New Agreement With Sanofi for Beacon® OptoFluidic Platform
Beacon Platform Adopted To Speed Cell Line Development
EMERYVILLE, Calif., April 19, 2018 /PRNewswire/ -- Berkeley Lights, Inc. (BLI), a company dedicated to bringing to market transformational platforms for biopharmaceutical processes, announced today Sanofi purchased the Beacon platform to accelerate their cell line development (CLD) process.
Based on data from the pilot study, the Beacon platform quickly and efficiently identified target secreting clones, which may save resources and expedite the discovery and development process. The four integrated workflows of Berkeley Lights' Beacon platform - import, culture, assay, and export - can be applied for cell line development, antibody discovery and engineering, gene editing, and research. Automating workflows using the Beacon platform increases efficiencies and reduces overall time while providing insights into the behavior of clonal populations, not possible using traditional techniques. The Beacon platform is capable of screening thousands of cells and clones in under a week.
"Berkeley Lights is committed to supporting our customers and helping them increase the scale and precision of their cell line development processes to innovate faster," said Eric Hobbs, PhD, CEO at Berkeley Lights, Inc. "Our mission is to deliver versatile platforms that combine biology, technology and information, enabling scientists to automate manual lab workflows and focus on discovery."
To learn more about the Beacon Cell Line Development (CLD) Workflow, visit https://www.berkeleylights.com/beacon-applications/cell-line-development/.
About Berkeley Lights:
Berkeley Lights, Inc. (BLI) is a digital cell biology company that develops and commercializes platforms for the acceleration of discovery, development, and delivery of cell-based products and therapies. At the intersection of biology, technology and information, our platforms automate the manipulation, analysis and selection of individual cells, creating ultimate scalability and deep cell insights. The Beacon platform* is ideally suited for cell line development, antibody discovery (including direct B-cell workflows), gene editing, and antibody engineering workflows. Each workflow provides 100-fold increase in insights, 10 times faster, at a fraction of the cost.
* For Research Use Only. Not for use in diagnostic procedures.
For more information, visit http://www.berkeleylights.com/.